Collaboration Funding. GSK shall be responsible for paying ARIDIS’ Development Costs specified in the budget incurred solely in connection with the conduct of the Collaboration Program (and not for activities outside of the conduct of the Collaboration Program or in furtherance of ARIDIS’ existing collaborations with Third Parties) in accordance with the applicable budget agreed upon by the Parties as specified in Exhibit B (the “Collaboration Funding”). GSK shall pay ARIDIS for the Collaboration Funding as set forth in Section 6.2. For the avoidance of doubt, GSK shall be responsible for all costs and expenses incurred by GSK to conduct the Collaboration Program.
Collaboration Funding. As consideration for the performance by Tekmira of its obligations under the Collaboration, Alnylam agrees to fund the FTEs provided by Tekmira as follows:
Collaboration Funding. The Collaboration Funds shall be applied by Isis solely towards the Collaboration and in accordance with the Collaborative Research Plan.
Collaboration Funding. Monsanto shall pay, or cause to be paid, to Alnylam a one-time, non-refundable payment of [**] Dollars ($[**]). Such payment shall be made in accordance with the payment schedule for deliverables set forth in the Discovery Collaboration agreement, but in no event later than [**] months after the Effective Date.
Collaboration Funding. In consideration of the performance by Translate Bio of the Translate Bio Collaboration Activities in the Collaboration, Sanofi shall pay Translate Bio the agreed sum set out in the Collaboration Budget for each of (a) FTE Costs, (b) Out-Of-Pocket Costs, and (c) Manufacturing Costs. Each of FTE Costs, Out-Of-Pocket Costs or Manufacturing Costs is a “Cost Category”) which shall be accounted for separately by Translate Bio and in no event shall Translate Bio include costs or expenses from one such Cost Category in another such Cost Category. In the event that the Collaboration Budget or Supply Agreement includes certain Out-of-Pocket Costs or Manufacturing Costs which Translate Bio is [**], Sanofi shall [**] the full amount of those Out-of-Pocket Costs and Manufacturing Costs to Translate Bio.
Collaboration Funding. In consideration for CombiChem's performance of its obligations under the Research Program, within *** of the Effective Date and within *** of the first *** of each subsequent *** interval of the Research Program Term, Teijin shall pay CombiChem an amount equal to *** of the Aggregate Annual Research Fee set forth below: Aggregate Contract Year Annual Research Fee The Aggregate Annual Research Fee shall be the maximum amount Teijin shall be obligated to pay CombiChem for its services as part of the Research Program (even if the product of the Annual Research Fee multiplied by the number of CombiChem scientists and Teijin scientists sited at CombiChem's facility and used in the Research Program on a FTE basis would exceed such amount) and CombiChem shall be responsible for any additional costs incurred by CombiChem, unless Teijin has agreed in writing in advance to pay any amount beyond the Aggregate Annual Research Fee. The amounts to be paid hereunder shall not be refundable nor shall they be creditable against any other amounts due under this Agreement. *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.
Collaboration Funding. Invitrogen shall pay to Illumina a non-refundable, non-creditable, collaboration payment of $2,300,000 (the "Collaboration Funding") in accordance with the following schedule:
Collaboration Funding. 5.2.1 MERCK shall pay for all costs and expenses incurred in performance of the Drug Development Plan, including manufacture and formulation of Compound and Product, costs incurred in all research and development, preclinical and clinical trials, pre-marketing and post-marketing studies and surveillance and manufacture of clinical supplies. None of these costs and expenses shall offset or be credited against any fees, royalties or other payments required to be made by MERCK to DOV under this Agreement.
Collaboration Funding. OMI will provide Collaboration funding to Isis as set forth in Section 3.5.2.
Collaboration Funding. In consideration for CombiChem's performance of its obligations under the Research Program, within *** of the Effective Date and within *** of the Research Program Term, Teijin shall pay CombiChem an amount equal to *** *** the Aggregate Annual Research Fee set forth below: *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.
